Search This Blog

Tuesday, October 27, 2026

Nautilus Biotechnology raises FY26 revenue outlook above ~$0.5M, guides Q4 sequential growth

 

after Q3 revenue beat to $234,000

  • Nautilus Biotechnology reported Q3 2026 net loss of $15.6M.
  • Held $114.3 million in cash, cash equivalents and investments as of September 30, 2026.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)